Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324362 · ClinicalTrials.gov registry record · Phase 4
GSK BHR Study (Sont - Second Study)
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 446
- Enrollment target
NCT01324362 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 446 participants.
The verdict
NCT01324362, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 446 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether asthma control and reduced bronchial responsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS BID or FP BID in adult and adolescent patients with persistent asthma
Interventions
- DRUG Placebo
- DRUG FP 100mcg
- DRUG FP 500mcg
- DRUG FP 250mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324362
The ClinicalTrials.gov registry entry for NCT01324362 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01324362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324362 about?
NCT01324362 is a clinical study titled "GSK BHR Study (Sont - Second Study)". The purpose of this study was to determine whether asthma control and reduced bronchial responsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS BID or FP BID in adult and adolescent patients with persistent asthma
What is the current status of trial NCT01324362?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 446 participants. The study started on 2003-01. Estimated completion is 2004-10.
What interventions are being tested in trial NCT01324362?
The interventions under investigation include: Placebo (DRUG), FP 100mcg (DRUG), FP 500mcg (DRUG), FP 250mcg (DRUG).
Who is sponsoring clinical trial NCT01324362?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.